NasdaqGM:FOLDBiotechs
How Strong Q2 Results and Pipeline Progress at Amicus Therapeutics (FOLD) Have Changed Its Investment Story
Amicus Therapeutics recently reported strong Q2 2025 revenue growth, highlighting key contributions from Galafold and Pompe therapies, and confirmed that full enrollment for its pivotal Phase III trial of DMX200 is on track by year-end.
The company reiterated its confidence in achieving positive GAAP net income in the second half of 2025 and projected combined sales of its core therapies to reach US$1 billion by 2028, reflecting confidence in both near-term and long-term prospects.
We'll now...